Loading…
← CockpitCompetitor Analysis › 002275.SZ Guilin Sanjin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Guilin Sanjin Pharmaceutical Co., Ltd. Class A002275.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.

≈ A Chinese TCM throat-lozenge maker (like a herbal Chloraseptic)Momentum leader 82
Mkt cap
$1.05B
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$79.7M
20-day average traded
Fwd P/E
12.8×
forward earnings
ROIC−WACC
+15.1 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥12.46
1D-3.6%
1W-18.8%
1M+2.3%
3M-7.4%
6M-11.8%
YTD-11.6%
1Y-17.8%
ATR %8.4%
52w lowhigh35.5% off high

What Guilin Sanjin Pharmaceutical does

Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.

Earns mostly from a few long-established over-the-counter products, led by Watermelon Frost, sold through distributors to pharmacies, so one brand carries the company. Because these are self-medication products, demand depends on brand recognition and pharmacy shelf space, not doctors' prescriptions.

In one line: A Chinese TCM throat-lozenge maker (like a herbal Chloraseptic).

Products and services

  • Watermelon frost throat spray/powder
  • Other OTC TCM products

Customers

  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • OTC throat/oral care remedies

What could go right

  • OTC throat-remedy demand

What could go wrong

  • OTC price competition

Moat: narrow (brand). Well-known heritage OTC brand for throat ailments with wide pharmacy distribution.

Headquarters: Guilin, Guangxi, China · Employees: 2,563

Named competitors

Guilin Sanjin Pharmaceutical at a glance

Size Guilin Sanjin Pharmaceutical (002275.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.05B, the 2061st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.46 on 18 Nov 2026.

Performance Over six months the shares fell 11.8%, against -12.4% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 2.6% over the last twelve months (peer median +6.3%); the operating margin is 24.4% (peer median 14.4%).

Valuation It trades at 12.8× forward earnings against a peer median of 18.4× (7th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 15.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026002275.SZ 91Peer median 87
Six months, rebased to 100: Guilin Sanjin Pharmaceutical against the median of its 20 peers (local-currency closes).

Guilin Sanjin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.03BCN¥2.03BCN¥2.17BCN¥2.15BCN¥1.94B
Revenue growth—-7%+1%+11%—
Gross profitCN¥1.60BCN¥1.49BCN¥1.55BCN¥1.51BCN¥1.32B
EBITDAn/aCN¥616MCN¥607MCN¥585MCN¥440M
Net incomeCN¥422MCN¥433MCN¥522MCN¥421MCN¥330M
Free cash flowCN¥630MCN¥633MCN¥515MCN¥479MCN¥473M
Capital expenditureCN¥94.6MCN¥123MCN¥82.2MCN¥76.4MCN¥62.3M
Total debtCN¥356MCN¥514MCN¥594MCN¥530MCN¥466M

Quarterly statements and history in the cockpit →

Guilin Sanjin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%07192142APNCRON002219PHNPHMBIOG-B64720460603262JWELSUDEEPPHRM2877300791600216600488300039300363002275.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Guilin Sanjin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×07192142APNCRON002219PHNPHMBIOG-B64720460603262JWELSUDEEPPHRM2877300791600216002275.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guilin Sanjin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%07192142APNCRONPHNPHMBIOG-B6472603262JWEL300791600216600488002275.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guilin Sanjin Pharmaceutical is the large dot.

Guilin Sanjin Pharmaceutical competitors and peer comparison

Head to head with its named competitors (002275.SZ vs 000999.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Guilin Sanjin Pharmaceutical 002275.SZ$1.05B-12%-3%24%12.8×-8.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Guilin Sanjin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guilin Sanjin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002275.SZPeer medianRank in peer set
1-month return+2.3%-3.7%6th highest of 21
6-month return-11.8%-12.4%11th highest of 21
Distance from 52-week high-35.5%-33.5%10th lowest of 21
Revenue growth (TTM)-2.6%+6.3%8th lowest of 21
Operating margin24.4%14.4%7th highest of 21
Forward P/E12.8×18.4×7th cheapest of 17
Growth the price implies (Req g, 7 yrs)-8.7%4.1%least demanding of 17
Growth delivered (Del g)+5.5%+14.3%5th lowest of 17
Hurdle (Req g minus delivered)-14.2 pp-8.8 pp3rd least demanding of 17
ROIC minus cost of capital+15.1 pp+2.5 pp7th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%

Questions

Who are Guilin Sanjin Pharmaceutical's main competitors?
Named competitors: China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes Shandong Xinhua Pharmaceutical (0719.HK), HBM (2142.HK), Applied Nutrition (APN.L), Cronos (CRON.TO), New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), PharmaNutra (PHN.MI).
Is Guilin Sanjin Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 12.8× against a peer median of 18.4×, 7th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Guilin Sanjin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -11.8% against -12.4% for the median peer; over one year -17.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.